Form 4: Alpha Tau Medical Insider Trading Activity

Raphi Levy, Chief Financial Officer of Alpha Tau Medical Ltd., reported transactions involving ordinary shares on July 6, 2026.

Summary

• Raphi Levy, the Chief Financial Officer of Alpha Tau Medical Ltd. (DRTS), reported transactions on July 6, 2026.
• Levy acquired 2,270 ordinary shares at a price of $2.98 per share.
• Concurrently, Levy disposed of 2,270 ordinary shares at a price of $14.00 per share.
• Following these transactions, Levy beneficially owns 90,180 ordinary shares directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While the CFO acquired shares at a lower price and sold at a higher price, indicating a profitable trade, the disposal of shares by an executive can sometimes be perceived negatively by the market.

Positives

• The CFO acquired shares, potentially indicating confidence in the company's future prospects.
• The acquisition price of $2.98 per share is significantly lower than the disposal price of $14.00 per share, suggesting a profitable transaction for the reporting person.

Negatives

• The disposal of a significant number of shares (2,270) by a key executive could be interpreted negatively by the market.

Future Outlook

This filing does not contain forward-looking statements or guidance.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The significant difference between the acquisition and disposal price for Alpha Tau Medical's CFO may reflect a pre-planned strategy or a personal financial decision, but the disposal of shares by an executive warrants attention from investors.

Stakeholder Impact

• Shareholders may interpret the disposal of shares by the CFO with mixed sentiment, potentially impacting short-term stock price fluctuations.
• Employees may view the transaction as a sign of executive confidence or a personal financial move.

Key Dates

Recommendation

The filing indicates a profitable transaction for the CFO, with shares acquired at a lower price and sold at a significantly higher price. However, the disposal of a substantial number of shares by a key executive warrants a cautious 'hold' stance until further clarity on the strategic implications, if any, is provided by the company.

Keywords

Alpha Tau Medical, DRTS, Form 4, Insider Trading, Share Transaction, Chief Financial Officer, Beneficial Ownership